Nektar Therapeutics (NKTR)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Investors who purchased Nektar securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Nektar and certain of its officers and/or directors have violated federal securities laws.
On March 14, 2022, Nektar and Bristol Myers Squibb issued a joint press release “announc[ing] an update following the first analysis of the Phase 3 PIVOT IO-001 study evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo (nivolumab) compared to Opdivo monotherapy as a first-line treatment for previously untreated unresectable or metastatic melanoma.” The two companies stated that “[f]ollowing a review of the study for efficacy and safety by an independent Data Monitoring Committee (DMC), Bristol Myers Squibb and Nektar were informed that the study did not meet the primary endpoints of progression-free survival (PFS) and objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR)” and that “[t]he DMC notified the companies that the third primary endpoint of overall survival (OS) did not meet statistical significance at the first interim analysis.” On this news, Nektar’s stock price fell $6.47 per share, or 60.87%, to close at $4.16 per share on March 14, 2022.
If you are aware of any facts relating to this investigation or purchased Nektar shares, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.